Evaluation of Safety and Efficacy of Estetrol in Healthy Men
The current study is designed as a phase Ib multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of E4 in healthy men after daily oral administration for 28 days.
Prostatic Neoplasms
DRUG: estetrol|DRUG: placebo
Number of participants with Adverse Events (AEs), Changes from baseline measurements considered clinically significant by the Investigator will be reported as AEs., 28 days|Change from baseline in hormone levels, The serum concentrations of Follicle Stimulating Hormone (FSH), Luteinising Hormone (LH), Estradiol (E2), total testosterone and free testosterone levels (actual values as well as percentage change from pre-dose concentration) will be listed and summarized descriptively by treatment group., 28 days
Change from baseline in haemostasis parameters, The relative change in Activated Protein C (APC)-resistance, prothrombin factor 1 + 2, D-dimer, free Tissue Factor Pathway Inhibitor (TFPI), antothrombin activity, protein S activity and angiotensinogen levels and the actual change from baseline will be calculated by treatment group., 28 days|Change from baseline in lipid parameters, The relative change in total cholesterol, triglycerides, High Density Lipoprotein (HDL) cholesterol, Low Density Lipoprotein (LDL) cholesterol, Lipoprotein A (Lp(A)) levels and the actual change from baseline will be calculated by treatment group., 28 days|Change from baseline in glucose levels, The relative change in glucose levels and the actual change from baseline will be calculated by treatment group., 28 days|Change from baseline in bone turnover markers, The relative change in osteocalcin, type I collagen telopeptide (CTX-1) and parathyroid hormone (PTH) and the actual change from baseline will be calculated by treatment group., 28 days|Change from baseline in sex-hormone binding globulin (SHBG) levels, The relative change in SHBG levels and the actual change from baseline will be calculated by treatment group., 28 days|Pharmacokinetic effect of estetrol, Area under the plasma concentration versus time curve (AUC), 28 days|Pharmacokinetic effect of estetrol, Terminal elimination half-life (t1/2), 28 days|Pharmacokinetic effect of estetrol, Time to reach Cmax (tmax), 28 days|Pharmacokinetic effect of estetrol, Peak plasma concentration (Cmax), 28 days
The current study is designed as a phase Ib multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of E4 in healthy men after daily oral administration for 28 days.